Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR) said it will participate at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026.
Company management, including Paul Josephs (chief executive officer) and Ryan Lake (chief financial officer), are scheduled to participate in 1-on-1 meetings during the conference.
Positive
- None.
Negative
- None.
News Market Reaction – LFCR
In the Dec 16 session, LFCR declined 2.16%, reflecting a moderate negative market reaction. Argus tracked a peak move of +8.7% during that session. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 11 | Investor conferences | Positive | +6.2% | Participation in Jefferies and Stephens conferences with presentations and meetings. |
| Nov 06 | Earnings update | Positive | -2.2% | Q3 2025 results with revenue growth, better EBITDA, and guidance details. |
| Oct 30 | Earnings scheduling | Neutral | +1.3% | Announcement of Q3 results date and related investor webcast details. |
| Oct 29 | New CDMO contract | Positive | +2.3% | New commercial manufacturing agreement and pre-clinical formulation deal. |
| Oct 28 | Collaboration deal | Positive | +2.5% | Collaboration with PolyPeptide for end-to-end peptide manufacturing in U.S. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news on collaborations, new manufacturing deals, and conference participation generally saw positive price reactions, while a fundamentally stronger earnings report drew a modest negative move, indicating occasional divergence on financial updates.
Over the last few months, Lifecore announced multiple strategic steps: a peptide manufacturing collaboration on Oct 28, 2025, a new commercial manufacturing partnership on Oct 29, 2025, and plans for reporting Q3 results on Nov 6, 2025. The actual Q3 earnings release showed revenue growth and improved profitability metrics but was followed by a small decline. Subsequent conference participation news on Nov 11, 2025 coincided with a stronger positive move. Today’s J.P. Morgan conference participation fits this pattern of ongoing investor outreach and business development visibility.
Key Terms
contract development and manufacturing organization technical
cdmo technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 44th Annual J.P. Morgan Healthcare Conference. The conference will take place January 12-15, 2026, in San Francisco, California.
Details regarding Lifecore’s participation are as follows:
- 44th Annual J.P. Morgan Healthcare Conference
Details: Lifecore management, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will participate in 1-on-1 meetings
Conference Dates: January 12-15, 2026
Location: San Francisco, California
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) 415-675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com